文章摘要
多西他赛联合香菇多糖治疗乳腺浸润性导管癌的疗效分析
Clinical analysis of docetaxel combined with lentinan in the treatment of infiltrating duct carcinoma of breast
投稿时间:2022-12-29  修订日期:2022-12-29
DOI:
中文关键词: 乳腺浸润性导管癌  多西他赛  香菇多糖
英文关键词: Infiltrating duct carcinoma  Docetaxel  Lentinan
基金项目:
作者单位邮编
毛玲 句容市人民医院 212400
左念 句容市人民医院 
摘要点击次数: 12
全文下载次数: 0
中文摘要:
      目的 探讨多西他赛(Docetaxel, DCT)即T方案或联合香菇多糖治疗乳腺浸润性导管癌的临床疗效及安全性分析。方法 收集2018年01月至2022年11月句容市人民医院收治的手术后乳腺浸润性导管癌患者80例。采取分别抽样法分组,分单药组(n=40例)及联合组(n=40例)。单药组给予多西他赛单药化疗(75mg/㎡);联合组给予多西他赛化疗(75mg/㎡)和香菇多糖辅助治疗。共治疗4周期,每2周期治疗结束后评估患者的客观缓解率、临床获益率、外周血肿瘤指标癌胚抗原(Carcinoembryonic Antigen, CEA)、糖类抗原15-3(Carbohydrate Antigen, CA15-3)、细胞因子IL-2、IL-4及T淋巴细胞亚群水平变化及不良反应。结果 联合组患者的客观缓解率、临床获益率高于单药组,差异均有统计学意义(P <0.05);联合组患者的外周血CEA、 CA15-3水平低于单药组,差异均有统计学意义(P <0.05);联合组IL-2水平高于单药组、IL-4水平低于单药组,差异有统计学意义(P<0.05);联合组CD4+、CD4+/CD8+ 水平高于单药组,差异有统计学意义(P<0.05)。联合组的化疗后骨髓抑制、胃肠道反应(恶心、呕吐)、肝和肾功能受损、脱发5种不良反应发生率低于单药组,差异有统计学意义(p <0.05)。结论 多西他赛联合香菇多糖治疗乳腺浸润性导管癌的临床疗效优于单药多西他赛化疗,能增强抗肿瘤活性,降低血清肿瘤标志物CEA及CA15-3水平,能有效调节细胞因子IL-2、IL-4水平,调节免疫功能,患者耐受性良好及不良反应低,值得临床应用。
英文摘要:
      Objective To investigate the clinical efficacy and safety of docetaxel alone and lentinan in the treatment of infiltrating duct carcinoma of breast. Methods From January 2018 to November 2022, 80 patients with invasive ductal carcinoma of breast after operation in Jurong People’s Hospital were collected. They were divided into single drug group (n=40) and combined group (n=40) by sampling. The monotherapy group was given docetaxel monotherapy (75 mg/㎡); The combination group was given docetaxel chemotherapy (75mg/㎡) and lentinan adjuvant treatment. There were 4 cycles of treatment. After every 2 cycles of treatment, the objective remission rate, clinical benefit rate, changes of tumor indexes of peripheral blood such as CEA, CA15-3, IL-2, IL-4, T lymphocyte subsets and adverse reactions were evaluated. Results The objective response rate and clinical benefit rate of patients in the combination group were higher than those in the monotherapy group (P < 0.05). The levels of CEA and CA15-3 in peripheral blood of patients in the combination group were lower than those in the monotherapy group (P< 0.05). IL-2 level in the combination group was higher than that in the monotherapy group, while IL-4 level was lower than that in the monotherapy group(P< 0.05). The levels of CD4+ and CD4+/CD8+ in the combination group were higher than those in the monotherapy group (P < 0.05). The incidence rates of five adverse reactions including bone marrow inhibition, gastrointestinal reactions (nausea and vomiting), liver and renal impairment, and alopecia after chemotherapy in the combination group were lower than those of the monotherapy group (p <0.05). Conclusion The clinical efficacy of docetaxel combined with lentinan in the treatment of infiltrating duct carcinoma of breast is superior to that of docetaxel chemotherapy alone. It can enhance anti-tumor activity, reduce serum tumor markers CEA and CA15-3 levels, effectively regulate cytokine IL-2 and IL-4 levels, and regulate immune function. The patients have good tolerance and low adverse reactions, and it is worthy of clinical application.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭

扫码关注本刊微信公众号“健康动向”